Compare ConocoPhillips (COP) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs Davita Inc — how do they compare? ConocoPhillips trades at $134.1 (market cap $161.21B), while Davita Inc trades at $179.05 (market cap $11.29B). The key difference: ConocoPhillips is far larger — about 14.3× Davita Inc's market cap, and ConocoPhillips pays a 2.5% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and Davita Inc for 114 Days on average.
| COP | DVA | |
|---|---|---|
Market Cap | $161.21B | $11.29B |
Volume | 6,058,403 | 582,204 |
Sector | Energy | Health |
52-Week High | $141.22 | $240.96 |
52-Week Low | $85.66 | $103.87 |
Typical Hold Time | 79 Days | 114 Days |
Enterprise Value | $176.81B | $24.01B |
Dividend Yield | 2.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $134.10, up 3.28% today, showing strong momentum with two consecutive quarterly earnings beats. The stock exhibits bullish technical signals with moving averages supporting upward trends. Fundamentally, the company maintains solid profitability with 14.65% net income margin and reasonable valuation at 17.75 P/E ratio. Recent developments include a 20-year LNG supply agreement with Venture Global and potential asset sales in Norway and UK operations.
Outlook remains positive with 75% analyst buy ratings and $154.75 consensus price target suggesting 15% upside. Key opportunities include energy market strength and strategic LNG expansion, while risks involve oil price volatility and geopolitical exposure in Middle East operations. The company's strong cash flow generation supports shareholder returns through dividends and buybacks.
DaVita (DVA) trades at $179.02, up 1.26% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 6.05% net margins and 635% ROE. Recent partnerships with Humana expand value-based kidney care services, while institutional investors like BlackRock added significant positions. Revenue growth remains steady at $13.6B annually with improving profitability trends.
DVA presents a mixed outlook with strong operational performance offset by technical weakness. The 43% upside to consensus price target of $235.67 offers potential, but high debt levels and regulatory risks require monitoring. Recent earnings momentum and expanding Medicare partnerships support long-term growth, though current technical indicators suggest near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
